IQVIA Holdings Inc. $IQV Stock: Trillium Asset Management LLC Boosts Position

Trillium Asset Management LLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 541.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,490 shares of the medical research company’s stock after acquiring an additional 18,139 shares during the quarter. Trillium Asset Management LLC’s holdings in IQVIA were worth $5,778,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of IQV. Pension & Wealth Management Advisors Inc. purchased a new position in shares of IQVIA in the 3rd quarter valued at about $30,000. Compass Financial Management LLC purchased a new stake in IQVIA during the second quarter worth about $27,000. Elevation Wealth Partners LLC boosted its holdings in IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after buying an additional 105 shares in the last quarter. Balance Wealth Partners LLC acquired a new position in IQVIA during the third quarter worth about $43,000. Finally, Caitlin John LLC acquired a new position in IQVIA during the second quarter worth about $31,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research reports. Evercore lifted their price target on shares of IQVIA from $275.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. TD Cowen upped their price target on IQVIA from $288.00 to $307.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Barclays upped their price target on IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Truist Financial raised their price objective on IQVIA from $329.00 to $346.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Finally, UBS Group started coverage on IQVIA in a report on Wednesday, September 30th. They set a “buy” rating and a $345.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $294.21.

Insiders Place Their Bets

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sherbet sold 4,446 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the transaction, the insider directly owned 24,989 shares of the company’s stock, valued at $6,967,682.87. The trade was a 15.10% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

IQV traded down $5.67 during midday trading on Friday, reaching $265.44. 1,986,072 shares of the company’s stock were exchanged, compared to its average volume of 1,407,100. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The stock has a market capitalization of $43.74 billion, a PE ratio of 32.25, a P/E/G ratio of 2.41 and a beta of 1.16. The business’s 50-day moving average price is $267.55 and its 200 day moving average price is $211.88. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $284.50.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.26 by $0.08. The company had revenue of $4.43 billion for the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.00 earnings per share. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.